As USP looms, access your compliance of medication compounding standards now
EMAIL THIS STORY
| PRINT THIS STORY
October 1, 2018
Examine your hospital’s medication compounding process and your compliance level with upcoming standards as The Joint Commission (TJC) signals its increasing focus on compounding as a problem area.
In January, TJC unveiled a Medication Compounding Certification (MCC) program that’s open to all compounding pharmacies, not just those with TJC accreditation. The accreditor also called upon healthcare providers to work toward the elimination of medication compounding–related infections (MCRI) like the 2012 meningitis outbreak connected to a Boston company. Almost 800 patients were infected and more than 70 died.
“The health care community, including The Joint Commission, recognize that as the need for compounded medications continues to grow it is more important than ever to ensure safe policies and procedures are being appropriately and effectively implemented to prevent patient harm,” wrote Robert Campbell, PharmD, TJC field surveyor, in a TJC blog post in April.
Meanwhile, the U.S. Pharmacopeial Convention’s (USP) Chapter <800> “Hazardous Drugs; Handling in Healthcare Settings,” will become fully enforceable by regulators on December 1, 2019. Its regulations aim to protect the 8 million American healthcare workers who are potentially exposed to hazardous vapors/particles from the substances used in compounding each year. The chapter talks about the physical environment and equipment needed to maintain sterility and avoid inadvertently contaminating the employee. USP also has other extant chapters on sterile compounding, such as Chapters <797> and <795>.